Abstract
The title compound, C18H18BrN3O3S, a derivative of 1,3,4-oxadiazole, crystallizes in the triclinic space group P-1 with unit cell parameters a = 6.8731(3), b = 8.9994(4), c = 15.7099(6) Å, α = 92.779(3)°, β = 130.575(3)°, γ = 107.868(4)°, Z = 2. The dihedral angle between the mean planes of the planar naphthyl and morpholine (chair) rings with the planar oxadiazol ring is 50.1(8) and 76.8(6)°, respectively. The planar naphthyl ring is twisted 52.2(5)° with the mean plane of the morpholine ring. A group of four intermolecular close contacts are observed between a bromine atom and hydrogen atoms from the closely packed naphthyl, morpholine and oxy–methyl groups in the unit cell. These molecular interactions in concert with an additional series of π–π stacking interactions that occur between the center of gravity of the two 6-membered rings of the naphthalene group influence the twist angles of each of these three groups. A MOPAC AM1 calculation of the conformation energy of the crystal structure [226.0128(9) kcal] compared to that of the minimum energy structure after geometry optimization [29.9744(1) kcal] reveals a significantly reduced value. The twist angles of the three groups above also change after the AM1 calculation giving support to the influence of both intermolecular C–H···Br short-range interactions and Cg π–π stacking interactions on these angles which therefore play a role in stabilizing crystal packing.
Graphical Abstract
Crystal structure of 5-{[(6-bromonaphthalen-2-yl)oxy]methyl}-3-(morpholin-4-ylmethyl)-1,3,4-oxadiazole-2(3H)-thione, C18H18BrN3O3S, is reported and its geometric and packing parameters described and compared to a MOPAC computational calculation.
Similar content being viewed by others
References
Ainsworth C (1965) J Am Chem Soc 87:5800–5803. doi:10.1021/ja00952a056
Kulkarni AP, Tonzola CJ, Babel A, Jenekhe SA (2004) Chem Mater 16:4556–4573. doi:10.1021/cm049473l
Paik K, Baek NS, Kim HK, Lee J, Lee Y (2002) Macromol 35:6782–6791. doi:10.1021/ma020406r
Amir M, Kumar S (2007) Acta Pharm 57:31–45. doi:10.2478/v10007-007-0003-y
Rajak H, Kharya M, Mishra P (2007) Pharm Soc Jpn 127:1757–1764
Cai X, Grewal G, Mark LG, Anna TP (2003) USPat No.6555550
Verhyde B, Dehaen W (2001) J Org Chem 66:4062–4064. doi:10.1021/jo005772s
Wang Y, Sauer DR, Djurie SW (2006) Tetrahedron Lett 47:105–108. doi:10.1016/j.tetlet.2005.10.131
Ramalingam T, Deshmukh AA, Sattur PB, Sheth UK, Naik SR (1981) J Indian Chem Soc 58:269–271
Kagthara PR, Shah NS, Doshi RK, Parekh HH (1999) Indian J Chem 38B:572–576
Nagalakshmi G (2008) Indian J Pharm Sci 70:49–55
El-Emam AA, Al-Deeb OA, Al-Omar M (2004) Bioorg Med Chem 12:5107–5113. doi:10.1016/j.bmc.2004.07.033
Kucukguzel SG, Oruc EE, Rollas S, Sahin F, Ozbek A (2002) Eur J Med Chem 37:197–206. doi:10.1016/S0223-5234(01)01326-5
Honnalli SS, Ronald PM, Vijaybhasker K, Hukkeri VI, Kumar R (2005) Communio 11:505–508
Mullican MD, Wilson MW, Connor DT, Kostlan CR, Schrier DJ, Dyer RD (1993) J Med Chem 36:1090–1099. doi:10.1021/jm00060a017
Amir M, Kumar S (2004) Eur J Med Chem 39:535–545. doi:10.1016/j.ejmech.2004.02.008
Andreani A, Rambaldi M, Locatelli A, Pifferi G (1994) Eur J Med Chem 29:903–906. doi:10.1016/0223-5234(94)90115-5
Misra U, Hitkari K, Saxena AK, Gurtu S, Shankar K (1996) Eur J Med Chem 31:629–634. doi:10.1016/0223-5234(96)89559-6
Narayana B, Ashalatha BV, Vijaya Raj KK, Fernandes J, Sarojini BK (2005) Bioorg Med Chem 13:4638–4644. doi:10.1016/j.bmc.2005.04.068
Narayana B, Vijaya Raj KK, Ashalatha BV, Suchetha Kumari N (2005) Arch Pharm 338:373–377. doi:10.1002/ardp.200500974
Yathirajan HS, Bindya S, Ashalatha BV, Narayana B, Bolte M (2006) Acta Crystallogr E62:o4442–o4443
Sheldrick GM (1997) SHELXS97, SHELXL97. University of Gőttingen, Germany
Bruker (2006) SHELXTL, Bruker A XS Inc., Madison, Wisconsin, USA
Allen FH, Kennard O, Watson DG, Brammer L, Orpen AG, Taylor RJ (1987) Chem Soc Perkin Trans 2:S1–S19. doi:10.1039/p298700000s1
Cremer D, Pople JA (1975) J Am Chem Soc 97:1354–1358. doi:10.1021/ja00839a011
Cambridge Structural Database (2003–2007) Cambridge Crystallographic Centre, MOGUL.1.1.2
AM1 (Austin Model 1) (2007) Approximation together with the Hartree-Fock closed-shell (restricted) wavefunction was used and minimizations were teminnated at an r.m.s. gradient of less than 0.01 kJ mol−1 Å−1. Schmidt, J.R.; Polik, W.F. WebMO Pro, version 8.0.010e; WebMO, LLC: Holland, MI, USA. available from http://www.webmo.net
Acknowledgments
ANM thanks the University of Mysore for use of their research facilities. RJB acknowledges the NSF MRI program (grant No. CHE-0619278) for funds to purchase an X-ray diffractometer.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Jasinski, J.P., Butcher, R.J., Mayekar, A.N. et al. Synthesis and Crystal Structure of 5-[2-(6-bromonaphthalenyloxymethyl)]-3-(4-morpholinomethyl)-1,3,4-oxadiazole-2(3H)-thione. J Chem Crystallogr 39, 761–765 (2009). https://doi.org/10.1007/s10870-009-9570-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10870-009-9570-8